GHRP-2 vs GHRP-6: A Research Comparison
GHRP-2 and GHRP-6 are both synthetic hexapeptide agonists of the growth hormone secretagogue receptor (GHS-R1a), studied within ghrelin signaling and GH-secretion research. They share that receptor but differ in amino acid sequence and in the secretagogue-signaling profiles reported in research literature, which is why they are compared as distinct tool compounds rather than treated as interchangeable. Both are for research use only.
Mechanism contrast: one receptor, two sequences
Both GHRP-2 (pralmorelin) and GHRP-6 are synthetic hexapeptides studied as agonists of the growth hormone secretagogue receptor (GHS-R1a), the same receptor engaged by the endogenous ligand ghrelin. Where they diverge is sequence: GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) opens with an N-terminal histidine, while GHRP-2 (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2) substitutes a D-alanine and a D-2-naphthylalanine at the first two positions.
Research literature reports that these substitutions give GHRP-2 a different secretagogue-potency profile at GHS-R1a, while GHRP-6 is classically referenced for pronounced ghrelin-pathway, including appetite-related, signaling in preclinical models. These are mechanistic characterizations reported in secretagogue-pharmacology research, not human effects, and they are the reason the two are studied as separate tools.
Research context and clinical-literature status
GHRP-2 has the more developed clinical record of the pair. As pralmorelin, it was approved in Japan as a diagnostic agent for assessing growth hormone secretion, and human clinical research has studied GHRP-2 for its effect on GH release. GHRP-6 has likewise been examined in published human and animal secretagogue research.
Neither compound is approved as a therapeutic drug in the United States or European Union. These statements describe the state of the research literature in the third person; on this site both peptides are supplied strictly as research-use-only materials and neither is intended for human use.
Handling parity
Because the two peptides are close in size (GHRP-2 near 818.0 g/mol, GHRP-6 near 873.0 g/mol) and share the same lyophilized-hexapeptide format, their handling is essentially identical: both are stored as powder at -20°C protected from light, reconstituted with bacteriostatic water added gently against the vial wall, then refrigerated with freeze-thaw cycles minimized.
This handling parity is useful in comparative work, because it removes storage and reconstitution as confounding variables when the two are studied side by side. Each ships with a lot-matched Certificate of Analysis; confirm salt form and net peptide content there, since counterion differences change the mass weighed out.
How researchers choose between them
The choice usually follows the mechanistic question. A protocol focused on maximal secretagogue potency at GHS-R1a often references GHRP-2, while work concerned with the broader ghrelin-pathway profile that GHRP-6 is classically associated with may favor GHRP-6 as the original comparator; studies needing a within-family potency contrast use both together.
Because both act on the ghrelin/secretagogue receptor rather than the GHRH receptor, neither substitutes for a GHRH analog such as Sermorelin or CJC-1295. A related hexapeptide secretagogue, Hexarelin, extends the same tool family, so researchers pairing a secretagogue with a GHRH-pathway compound select across those families rather than only within the GHRP pair.
All products are intended strictly for in-vitro laboratory research and development use only. Not for human or veterinary use, not a drug, food, or cosmetic, and not intended to diagnose, treat, cure, or prevent any disease.